Purpose: To study the effectiveness of intravitreal aflibercept in high pigment epithelium detachment (PED) in eyes with age-related macular degeneration (AMD).
Material And Methods: This study included 16 eyes of 16 patients (10 female and 6 male) aged 52 to 82 years (mean age 68.56±2.31 years). Examination of patients included determination of best-corrected visual acuity (BCVA), biomicroscopy with Goldmann lens, photographic recording of the ocular fundus, optical coherence tomography (OCT) and OCT-angiography. Results of the treatment were evaluated 1 month after the third injection of aflibercept. Among the analyzed parameters were: BCVA, maximum PED height, resorption of perifocal neuroepithelium detachment (NED), expressiveness of hyperreflective content of PED.
Results: One months into the treatment, after the third injection, mean BCVA improved by 0.09 to 0.36±0.04, height of PED decreased in average by 225.3±44.6 µm to 326.88±25.13 µm. Complete resolution of PED was not achieved in any of the cases. Resulting mean height of perifocal PED was 61.25±12.87 µm. Full resorption of PED was achieved in 4 eyes. Expressiveness of hyperreflective content of PED higher than 50% was observed in 13 eyes (81.25%).
Conclusion: The results of intravitreal aflibercept in AMD patients with high PED have proved its effectiveness in reducing maximum PED height, improving resorption of perifocal NED and BCVA. Optically 'empty' PEDs had higher sensitivity to intravitreal aflibercept than hyperreflective PEDs. Statistically significant dependence of BCVA on the height and content of PED was absent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/oftalma201813405192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravitreal AAV-IKV Mediated Delivery of Decorin Inhibits Choroidal Neovascularization, Fibrosis, Inflammation and Elevates Autophagy.
Exp Eye Res
January 2025
Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111. Electronic address:
Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. The exudative or wet form of AMD is caused by choroidal neovascularization (CNV) and subsequently a macular edema. Wet AMD can be effectively treated with anti-vascular endothelial growth factor (VEGF) therapies.
View Article and Find Full Text PDFEffect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity.
Eur J Med Res
January 2025
Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Gongye Avenue Middle, Guangzhou, 510282, Guangdong, China.
Background: To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
Methods: We retrospectively reviewed the medical records of 176 eyes diagnosed with ROP and treated with anti-VEGF therapy between January 2018 and September 2022. The rate of reactivation and complications were assessed during the follow-up period.
Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis.
Clin Ophthalmol
January 2025
2nd Department of Ophthalmology, Medical School of University of Athens, "attikon" University Hospital, Athens, Greece.
Purpose: To evaluate the 2-year outcomes of resveratrol oral supplement given as an adjunctive treatment in patients with wet age-related macular degeneration (AMD) that were treated with intravitreal injections of aflibercept.
Patients And Methods: In our retrospective study, 50 treatment-naïve patients suffering from wet-AMD were included. They were assigned to two subgroups of 25 patients each.
Postpartum Exudation of Idiopathic Quiescent Macular Neovascularization: A Narrative Review with a Related Case Report.
Life (Basel)
December 2024
Eye Unit, Department of Medicine, Surgery, and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, SA, Italy.
The abnormal growth of irregular new blood vessels into the subretinal or intraretinal space is known as macular neovascularization (MNV). People over 50 are often affected by this disorder, which is typically brought on by age-related macular degeneration. In addition, MNV can be found in people under 50 years of age, who may present primary ophthalmic diseases such as pathological myopia, angioid streaks, traumatic choroidal rupture, or suspected ocular histoplasmosis syndrome.
View Article and Find Full Text PDFComparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis.
Int J Mol Sci
January 2025
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke-shi 329-0498, Tochigi, Japan.
Aflibercept and brolucizumab, two anti-VEGF agents used as intravitreal injections in ophthalmology, differ significantly in molecular weight (aflibercept-115 kDa and brolucizumab-26 kDa). Using aqueous humor samples collected after drug administration, we measured and performed a comparative analysis of pharmacokinetics and half-lives of these drugs in the human eye. Since the quantification of monoclonal antibodies (mAbs) using antigen-antibody reactions, such as ELISA, is influenced by endogenous ligands or anti-drug antibodies, we employed nano-surface and molecular-orientation limited proteolysis (nSMOL), combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS), for accurate measurements.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!